| Market Capitalization (Millions $) |
794 |
| Shares
Outstanding (Millions) |
42 |
| Employees |
452 |
| Revenues (TTM) (Millions $) |
288 |
| Net Income (TTM) (Millions $) |
-62 |
| Cash Flow (TTM) (Millions $) |
-17 |
| Capital Exp. (TTM) (Millions $) |
0 |
Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases. The company was founded in 2002 by Mark Pruzanski and is headquartered in New York City, with additional offices in London and San Diego. The company is publicly traded under the symbol ICPT on the NASDAQ stock exchange.
Intercept's flagship product is Ocaliva (obeticholic acid), which was approved by the US Food and Drug Administration (FDA) in 2016 for the treatment of primary biliary cholangitis (PBC), a rare and chronic autoimmune liver disease. Ocaliva is the first and only drug approved for the treatment of PBC in over 20 years. In 2019, Ocaliva was also approved in the European Union for the treatment of PBC.
In addition to PBC, Intercept has a pipeline of drug candidates under development for the treatment of nonalcoholic steatohepatitis (NASH), a fatty liver disease that can lead to liver damage, cirrhosis and cancer. NASH affects millions of people worldwide and is a major cause of liver-related morbidity and mortality. Intercept's most advanced NASH candidate is called obeticholic acid (OCA), which is being evaluated in several clinical trials.
Intercept's research and development efforts are focused on discovering and developing new drugs that target the underlying mechanisms of liver disease. The company leverages its expertise in liver biology, drug discovery and development, and clinical research to advance its pipeline of drug candidates. Intercept has collaborations and partnerships with leading academic institutions, research organizations, and pharmaceutical companies to enhance its research capabilities and bring new therapies to the market.
Intercept has received numerous awards and recognitions for its contributions to the biopharmaceutical industry and research in liver disease. The company is committed to creating value for patients, healthcare providers, and shareholders, and is well positioned for continued growth and success in the years to come.
Company Address: 305 Madison Avenue, Morristown 7960 NJ
Company Phone Number: 747-1000 Stock Exchange / Ticker: NASDAQ ICPT
|
